[HTML][HTML] Long-acting β2-agonists in asthma: safety concerns
E Wooltorton - Cmaj, 2005 - Can Med Assoc
Note: MDI= metered-dose inhaler, RR= relative risk, CI= confidence interval.* Adapted from
Chowdhury BA. Division director memorandum [overview of the FDA background materials …
Chowdhury BA. Division director memorandum [overview of the FDA background materials …
Long-acting β₂ agonists for asthma: a clinical paradox.
D Williams - The Consultant Pharmacist: the Journal of the …, 2010 - europepmc.org
This action is the most recent in a long history of concerns and controversies about the
safety of these agents. The changes are based on FDA's analyses of studies that …
safety of these agents. The changes are based on FDA's analyses of studies that …
Evaluating safety of long-acting beta agonists (LABAs) in patients with asthma
B Bian, C ML Kelton, PR Wigle, JJ Guo - Current Drug Safety, 2010 - ingentaconnect.com
The introduction of long-acting beta agonists (LABAs) was considered a major advance in
bronchodilator therapy with evidence that their use led to improved lung function and quality …
bronchodilator therapy with evidence that their use led to improved lung function and quality …
Are there any detrimental effects of the use of inhaled long-acting β2-agonists in the treatment of asthma?
MAB Devoy, RW Fuller, JBD Palmer - Chest, 1995 - journal.chestnet.org
For editorial comment see page 889 treatment guidelines agree that they are the agents of
choice to relieve bronchoconstriction in acute asthma. 1· 2 There has been considerable …
choice to relieve bronchoconstriction in acute asthma. 1· 2 There has been considerable …
Safety of long-acting beta-agonists—an urgent need to clear the air
FD Martinez - New England Journal of Medicine, 2005 - Mass Medical Soc
Safety of Long-Acting Beta-Agonists — An Urgent Need to Clear the Air | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
The beta-agonist controversy
DR Taylor, MR Sears, DW Cockcroft - Medical Clinics, 1996 - medical.theclinics.com
BACKGROUND Despite widespread use of adrenergic agents in the management of
asthma for many decades, doubts have emerged concerning the safety and efficacy of long …
asthma for many decades, doubts have emerged concerning the safety and efficacy of long …
[HTML][HTML] Food and drug Administration–mandated trials of long-acting β-Agonist safety in asthma. bang for the buck?
The uncertainty regarding the safety of longacting b-agonists (LABAs) in the treatment of
asthma has been lingering for the last 25 years, an ongoing concern for patients, clinicians …
asthma has been lingering for the last 25 years, an ongoing concern for patients, clinicians …
FDA's Recommendations on the Use of Long-Acting β2 Agonists in the Management of Asthma
CA Robinson - Annals of Pharmacotherapy, 2010 - journals.sagepub.com
The revised labeling for long-acting β2 agonists (LABAs) by the Food and Drug
Administration (FDA) is controversial and in part is inconsistent with the 2007 National …
Administration (FDA) is controversial and in part is inconsistent with the 2007 National …
[HTML][HTML] Long-acting β-agonists and asthma: the saga continues
AE Dixon - American journal of respiratory and critical care …, 2011 - atsjournals.org
Long-acting b-agonists (LABAs) were originally approved for the treatment of asthma in the
early 1990s. Despite nearly 20 years of experience with these medications, there is a storm …
early 1990s. Despite nearly 20 years of experience with these medications, there is a storm …
[HTML][HTML] The FDA and safe use of long-acting beta-agonists in the treatment of asthma
BA Chowdhury, G Dal Pan - New England Journal of Medicine, 2010 - Mass Medical Soc
The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma | NEJM Skip to
main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare …
main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare …